Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307857 | 0.92 | ALPL (0.40) | ALPLTSHRNOTUMMAPTALDH1A1 | |
| SCHEMBL6308462 | 0.92 | ALPL (0.45) | ALPLTSHRNOTUMMAPK1MAPT | |
| SCHEMBL6305873 | 0.88 | LMNA (0.41) | ALPLTSHRNOTUMMAPTPOLB | |
| SCHEMBL6308615 | 0.87 | RAB9A (0.41) | ALPLTSHRNOTUMMAPK1MAPT | |
| SCHEMBL6307570 | 0.86 | MAPT (0.36) | MAPTPOLBSMN1; SMN2 | |
| SCHEMBL27602670 | 0.83 | TSHR (0.38) | ALPLTSHRNOTUMMAPK1MAPT | |
| SCHEMBL6314118 | 0.82 | ALPL (0.42) | ALPLTSHRNOTUMMAPTPOLB | |
| SCHEMBL6306511 | 0.82 | KDM4E (0.43) | TSHRNOTUMALDH1A1NPC1RAB9A | |
| SCHEMBL5663447 | 0.81 | FDPS (0.44) | TSHRNOTUMMAPK1POLBALDH1A1 | |
| SCHEMBL6314585 | 0.80 | LMNA (0.41) | ALPLTSHRNOTUMMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | claimed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | claimed |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | ILEX PRODUCTS, INC. | 2005-08-25 | — | — | US | disclosed |
| US-6706698-B2 | ANTICHOLESTEROL AGENTS | ILEX PRODUCTS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | PHAN HIEU TRUNG (CH) | 2003-06-19 | — | — | US | disclosed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | ALPL 634/4885TSHR 4540/4885NOTUM 1114/4885 |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | ALPL 634/4885TSHR 4540/4885NOTUM 1114/4885 |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | APOB, LDLR, HDLBP | ALPL 1430/4885TSHR 4237/4885NOTUM 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.